Mirati Therapeutics Inc (MRTX.OQ)
16 Mar 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2016||Executive Chairman of the Board|
|59||2012||President, Chief Executive Officer, Director|
|41||2016||Chief Financial Officer, Senior Vice President|
|52||2013||Chief Medical and Development Officer, Executive Vice President|
|2016||Executive Vice President, Chief Business Officer|
- BRIEF-Mirati Therapeutics Q4 Loss Per Share $0.67
- BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
- BRIEF-Mirati announces advancement of opportunities with inhibitor programs
- BRIEF-Mirati Therapeutics reports Q3 loss per share of $0.65
- BRIEF-Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients